OwlTail

Cover image of Atopic Dermatitis

Atopic Dermatitis

44 Podcast Episodes

Latest 6 Nov 2021 | Updated Daily

Weekly hand curated podcast episodes for learning

Episode artwork

Lisa A. Beck, MD - Integrating the Latest Evidence Into Practice: Expert Insights on Targeted Biologic Therapy for Pediatric and Adult Patients With Moderate to Severe Atopic Dermatitis

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Go online to PeerView.com/RSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert dermatologist discusses the latest evidence from the 30th European Academy of Dermatology and Venereology Congress for current and emerging targeted biologic therapies for moderate to severe atopic dermatitis in adults and children. Upon completion of this accredited CE activity, participants should be better able to: Interpret recent developments in clinical research and treatment guidelines regarding the management of pediatric and adult patients with moderate to severe atopic dermatitis, Apply the latest clinical evidence on approved and emerging biologic therapies into personalized treatment plans for pediatric and adult patients with moderate to severe atopic dermatitis.

25mins

3 Nov 2021

Episode artwork

Lisa A. Beck, MD - Integrating the Latest Evidence Into Practice: Expert Insights on Targeted Biologic Therapy for Pediatric and Adult Patients With Moderate to Severe Atopic Dermatitis

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Go online to PeerView.com/RSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert dermatologist discusses the latest evidence from the 30th European Academy of Dermatology and Venereology Congress for current and emerging targeted biologic therapies for moderate to severe atopic dermatitis in adults and children. Upon completion of this accredited CE activity, participants should be better able to: Interpret recent developments in clinical research and treatment guidelines regarding the management of pediatric and adult patients with moderate to severe atopic dermatitis, Apply the latest clinical evidence on approved and emerging biologic therapies into personalized treatment plans for pediatric and adult patients with moderate to severe atopic dermatitis.

25mins

3 Nov 2021

Similar People

Episode artwork

Lisa A. Beck, MD - Integrating the Latest Evidence Into Practice: Expert Insights on Targeted Biologic Therapy for Pediatric and Adult Patients With Moderate to Severe Atopic Dermatitis

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Go online to PeerView.com/RSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert dermatologist discusses the latest evidence from the 30th European Academy of Dermatology and Venereology Congress for current and emerging targeted biologic therapies for moderate to severe atopic dermatitis in adults and children. Upon completion of this accredited CE activity, participants should be better able to: Interpret recent developments in clinical research and treatment guidelines regarding the management of pediatric and adult patients with moderate to severe atopic dermatitis, Apply the latest clinical evidence on approved and emerging biologic therapies into personalized treatment plans for pediatric and adult patients with moderate to severe atopic dermatitis.

25mins

3 Nov 2021

Episode artwork

Jonathan I. Silverberg, MD, PhD, MPH - Test Your Knowledge of New and Emerging Therapies for Moderate to Severe Atopic Dermatitis: Latest Evidence and Clinical Potential

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Go online to PeerView.com/FXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses new and emerging therapies for patients with moderate to severe atopic dermatitis. Upon completion of this accredited CE activity, participants should be better able to: Describe key cytokine signaling pathways involved in the pathogenesis of atopic dermatitis (AD) and implications for treatment, Evaluate recent clinical trial data related to the efficacy and safety of new and emerging treatment options (eg, JAK inhibitors) for moderate to severe AD, Treat AD in accordance with current evidence and guidelines, identifying patients with moderate to severe disease who would likely derive benefit from novel therapeutic options, Discuss evidence and recommendations on the immunization and monitoring of patients with AD who are candidates for, or receiving, biological or small-molecule targeted immunomodulatory therapies.

27mins

1 Oct 2021

Most Popular

Episode artwork

Jonathan I. Silverberg, MD, PhD, MPH - Test Your Knowledge of New and Emerging Therapies for Moderate to Severe Atopic Dermatitis: Latest Evidence and Clinical Potential

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Go online to PeerView.com/FXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses new and emerging therapies for patients with moderate to severe atopic dermatitis. Upon completion of this accredited CE activity, participants should be better able to: Describe key cytokine signaling pathways involved in the pathogenesis of atopic dermatitis (AD) and implications for treatment, Evaluate recent clinical trial data related to the efficacy and safety of new and emerging treatment options (eg, JAK inhibitors) for moderate to severe AD, Treat AD in accordance with current evidence and guidelines, identifying patients with moderate to severe disease who would likely derive benefit from novel therapeutic options, Discuss evidence and recommendations on the immunization and monitoring of patients with AD who are candidates for, or receiving, biological or small-molecule targeted immunomodulatory therapies.

27mins

1 Oct 2021

Episode artwork

Jonathan I. Silverberg, MD, PhD, MPH - Test Your Knowledge of New and Emerging Therapies for Moderate to Severe Atopic Dermatitis: Latest Evidence and Clinical Potential

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/FXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses new and emerging therapies for patients with moderate to severe atopic dermatitis. Upon completion of this accredited CE activity, participants should be better able to: Describe key cytokine signaling pathways involved in the pathogenesis of atopic dermatitis (AD) and implications for treatment, Evaluate recent clinical trial data related to the efficacy and safety of new and emerging treatment options (eg, JAK inhibitors) for moderate to severe AD, Treat AD in accordance with current evidence and guidelines, identifying patients with moderate to severe disease who would likely derive benefit from novel therapeutic options, Discuss evidence and recommendations on the immunization and monitoring of patients with AD who are candidates for, or receiving, biological or small-molecule targeted immunomodulatory therapies.

27mins

1 Oct 2021

Episode artwork

Peter A. Lio, MD - Overcoming Challenges in the Management of Moderate to Severe Atopic Dermatitis: Practical Strategies for Selecting Treatment for Pediatric and Adult Patients

PeerView Clinical Pharmacology CME/CNE/CPE Video

Go online to PeerView.com/XAZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in atopic dermatitis discusses practical strategies for selecting treatment for pediatric and adult patients. Upon completion of this accredited CE activity, participants should be better able to: Summarize the pathophysiologic mechanisms and risk factors that contribute to the development of atopic dermatitis, Discuss the clinical evidence and mechanistic rationale for the use of biologic therapies in the treatment of moderate to severe atopic dermatitis, Develop treatment plans for adult and pediatric patients with moderate to severe atopic dermatitis to prevent flare-ups, manage comorbidities, maximize health-related quality of life, and minimize treatment-related side effects, Employ strategies to communicate and collaborate with patients and caregivers to improve their understanding of atopic dermatitis and the importance of treatment adherence.

30mins

20 Sep 2021

Episode artwork

Peter A. Lio, MD - Overcoming Challenges in the Management of Moderate to Severe Atopic Dermatitis: Practical Strategies for Selecting Treatment for Pediatric and Adult Patients

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Go online to PeerView.com/XAZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in atopic dermatitis discusses practical strategies for selecting treatment for pediatric and adult patients. Upon completion of this accredited CE activity, participants should be better able to: Summarize the pathophysiologic mechanisms and risk factors that contribute to the development of atopic dermatitis, Discuss the clinical evidence and mechanistic rationale for the use of biologic therapies in the treatment of moderate to severe atopic dermatitis, Develop treatment plans for adult and pediatric patients with moderate to severe atopic dermatitis to prevent flare-ups, manage comorbidities, maximize health-related quality of life, and minimize treatment-related side effects, Employ strategies to communicate and collaborate with patients and caregivers to improve their understanding of atopic dermatitis and the importance of treatment adherence.

29mins

20 Sep 2021

Episode artwork

Peter A. Lio, MD - Overcoming Challenges in the Management of Moderate to Severe Atopic Dermatitis: Practical Strategies for Selecting Treatment for Pediatric and Adult Patients

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Go online to PeerView.com/XAZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in atopic dermatitis discusses practical strategies for selecting treatment for pediatric and adult patients. Upon completion of this accredited CE activity, participants should be better able to: Summarize the pathophysiologic mechanisms and risk factors that contribute to the development of atopic dermatitis, Discuss the clinical evidence and mechanistic rationale for the use of biologic therapies in the treatment of moderate to severe atopic dermatitis, Develop treatment plans for adult and pediatric patients with moderate to severe atopic dermatitis to prevent flare-ups, manage comorbidities, maximize health-related quality of life, and minimize treatment-related side effects, Employ strategies to communicate and collaborate with patients and caregivers to improve their understanding of atopic dermatitis and the importance of treatment adherence.

30mins

20 Sep 2021

Episode artwork

70. Modern treatments for psoriasis and atopic dermatitis, Todd Zavodnick, CEO, Dermavant Sciences

Biotech 2050 Podcast

Todd Zavodnick has over 20 years of leadership experience in the biopharmaceutical industry. Prior to joining Dermavant in November 2018, Mr. Zavodnick served as Chief Commercial Officer and President of Aesthetics and Therapeutics at Revance. He served in global leadership roles at ZELTIQ Aesthetics prior to the company’s acquisition by Allergan; at Galderma Laboratories, where he was President and General Manager of North America; and at Alcon Laboratories. He is a member of the board of directors of the Children’s Skin Disease Foundation.On August 10, 2021, after this interview was recorded, Dermavant Sciences announced that the FDA accepted for filing a New Drug Application (NDA) for tapinarof for the treatment of plaque psoriasis in adult patients. Tapinarof is an investigational, novel, therapeutic aryl hydrocarbon receptor modulating agent, in development as a once-daily, steroid-free and cosmetically elegant topical cream for the treatment of plaque psoriasis and atopic dermatitis. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date in Q2 2022.

28mins

25 Aug 2021

Loading